Open Label intranasal oxytocin

Phase 2Small molecule

Open Label intranasal oxytocin is one of 12 small molecule programs targeting Social Behavior. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Social BehaviorActive, not recruiting

Social BehaviorPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Social Behavior

#DrugCompanyPhaseTrials

Influenza Vaccine

Novartis

Approved

1 2

Ethanol

Roche

Phase 2

1 3

Ritalin

Novartis

Phase 1

1 4

Tasmar

BBausch Health Americas, Inc.

Phase 1

1 5

Intranasal Oxytocin

UUniversity of Electronic Science and Technology of China

Phase 1

2 6

Psilocybin

COMPASS Pathways

Phase 1

1 7

Pitocin

RRetrophin

Preclinical

2 8

Midomafetamine

LLykos Therapeutics

Phase 1

—9

Open Label intranasal oxytocin

LLinmarie Sikich

Phase 2

1 10

Arginine Vasopressin

SStanford University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Social Behavior1 trial

Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

Completed·LLinmarie Sikich·Phase 2·NCT01944046·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Open Label intranasal oxytocin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Open Label intranasal oxytocin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Open Label intranasal oxytocin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Linmarie Sikich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLinmarie Sikich

Open Label intranasal oxytocin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Social Behavior1 trial

References

Drug Info

Quick Facts

Related News